Oxford Biomedica PLC Director/PDMR Shareholding (0116A)
September 24 2020 - 3:36AM
UK Regulatory
TIDMOXB
RNS Number : 0116A
Oxford Biomedica PLC
24 September 2020
PDMR Dealings / Market Share sale
Oxford, UK - 24 September 2020: Oxford Biomedica plc ("Oxford
Biomedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, was informed that on 22 September 2020, that Dr.
Kyriacos Mitrophanous, Chief Scientific Officer of the Group,
exercised 9,255 DBP (2016) options at nil cost, exercised 19,623
LTIP (2015) options at nil cost and sold all of the resulting
shares at 837p. He also exercised 6,547 LTIP (2014) options at 50p
and sold all the resulting shares at 837p. Following these
transactions Dr. Mitrophanous holds 172,476 options and no shares
in the Company.
The issued share capital of the Group is 82,185,673 ordinary 50p
shares.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares sold.
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Chief Scientific Officer
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford BioMedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------
b) Nature of the Exercise of options
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
Nil 9,255
----------
Nil 19,623
----------
GBP0.50 6,547
----------
----------------------------- -----------------------------------
e) Aggregated information 35,425
* Aggregate volume GBP0.092
GBP3,273.50
* Price
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2020-09-22
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Chief Business Officer
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford BioMedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------
b) Nature of the Disposal
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP8.37 9,255
----------
GBP8.37 19,623
----------
GBP8.37 6,547
----------
----------------------------- -----------------------------------
e) Aggregated information 35,425
* Aggregate volume GBP8.37
GBP296.507.25
* Price
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2020-09-22
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a three-year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 580 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGIGDCSXDDGGS
(END) Dow Jones Newswires
September 24, 2020 04:36 ET (08:36 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024